Purpose of review
This article, focus on recently published data of the last 18 months on the management of gynecologic sarcomas.
Different tools have been studied to identify the differences between benign from malignant uterine conjonctive tumor.
Molecular biology impact more and more on the diagnosis of uterine sarcoma with new definitions of very specific groups. This will make it possible to better define the last group of endometrial sarcoma which has been defined as undifferentiated.
In several articles, surgical approaches and fertility-sparing surgery were described including the role of surgery for recurrences.
Some other articles have evaluated the potential benefice of adjuvant therapy for uterine sarcoma with early stages.
Several new targeted therapies are in development. Notably deoxyribonucleic acid repair machinery in uterine leiomyosarcoma and also immune therapies, transforming growth factor beta pathway, mechanistic target of rapamycin inhibitor, anti angiogenics, etc.
This last year the potential interest for uterine sarcoma increased, demonstrated by the increasing number of publications in the literature compared to previous years. Despite this greater interest over time, the standard of care for uterine sarcoma does not change and we are always waiting for new innovative therapies able to change routine practice and survival of patients. Currently, the result of different clinical trials, which include new options as targeted molecular approach or immune checkpoint inhibitors are closed to be reported.